Medios AG

ILM1

DE000A1MMCC8

Pharmaceuticals

Market Closed - Xetra Other stock markets 11:36:10 2024-06-21 EDT			5-day change	1st Jan Change
16.68 ^EUR	-1.65%		+4.38%	+5.17%

06-20	Medios Founder Sells 15% Stake to Investment Company Luxempart	MT
06-06	Medios at two-month high after buy recommendation	DP

NVR: Medios AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

June 11, 2024 at 07:35 am

EQS Total Voting Rights Announcement: Medios AG / Total Voting Rights Announcement
Medios AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

11.06.2024 / 13:34 CET/CEST
Total Voting Rights Announcement transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Publication of new total number of voting rights according to Sec. 41 WpHG

1. Details of issuer

Medios AG
Heidestraße 9
10557 Berlin
Germany

2. Type of capital measure or other measure

	Type of capital measure or other measure	Date of status / date of effect
	Conditional capital increase (Sec. 41 para. 2 WpHG)
X	Other (capital) measure (Sec. 41 para. 1 WpHG)	11 Jun 2024

3. New total number of voting rights:

25.505.723
number of multiple voting rights thereof: 0

11.06.2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

Language:	English
Company:	Medios AG
	Heidestraße 9
	10557 Berlin
	Germany
Internet:	www.medios.ag


End of News	EQS News Service

1922703 11.06.2024 CET/CEST

Latest news about Medios AG

Medios Founder Sells 15% Stake to Investment Company Luxempart	06-20	MT
Medios at two-month high after buy recommendation	06-06	DP
Medios AG acquired Ceban B.V. from Bencis Capital Partners B.V.	06-05	CI
Medios AG Reports Earnings Results for the First Quarter Ended March 31, 2024	05-06	CI
Transcript : Medios AG, Q1 2024 Earnings Call, May 07, 2024	05-06
Medios AG Reports Earnings Results for the Full Year Ended December 31, 2023	03-27	CI
Medios AG Provides Earnings Guidance for the Year 2024	03-17	CI
Transcript : Medios AG, Ceban B.V. - M&A Call	03-17
Medios AG agreed to acquire Ceban B.V. from Bencis Capital Partners B.V. for ? 259 million.	03-17	CI
Medios AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Transcript : Medios AG, Q3 2023 Earnings Call, Nov 14, 2023	11-14
Medios AG Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Transcript : Medios AG, H1 2023 Earnings Call, Aug 14, 2023	23-08-13
Medios to Sell Kölsche Blister Unit Amid Plan to Centralize Blister Business in Germany	23-06-19	MT
Medios AG Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Transcript : Medios AG, Q1 2023 Earnings Call, May 11, 2023	23-05-10
Medios AG Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-29	CI
Medios AG Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-29	CI
Transcript : Medios AG, 2022 Earnings Call, Mar 30, 2023	23-03-29
Medios: Countering price pressure in specialty pharmaceuticals - 2022 targets achieved	23-01-31	DP
Medios aims to counter price pressure in specialty pharmaceuticals - 2022 targets achieved	23-01-31	DP
Medios Closes Purchase of Germany's Blisterzentrum Baden-Württemberg	23-01-10	MT
Medios AG completed the acquisition of Blisterzentrum Baden-Württemberg GmbH.	23-01-09	CI
Medios AG(XTRA:ILM1) dropped from Germany SDAX (Total Return) Index	22-12-16	CI
MEDIOS : Buy rating from Deutsche Bank	22-11-25	ZD

Chart Medios AG

Duration

Period

More charts

Company Profile

Medios AG, formerly Crevalis Capital AG, is a Germany-based company that is active in the pharmacy business. It wholesales, markets, distributes and produces various kinds of goods for pharmacies and other pharmaceutical companies. The Company also provides related services and is engaged in the acquisition and management of other companies from the pharmaceutical industry.

Sector

Pharmaceuticals

Calendar

2024-08-12 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Medios AG

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

16.68 EUR

Average target price

32 EUR

Spread / Average Target

+91.85%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
MEDIOS AG	+5.17%	455M
ELI LILLY AND COMPANY	+51.63%	796B
NOVO NORDISK A/S	+41.51%	628B
JOHNSON & JOHNSON	-5.10%	358B
MERCK & CO., INC.	+19.90%	331B
ABBVIE INC.	+9.95%	301B
ASTRAZENECA PLC	+17.66%	244B
ROCHE HOLDING AG	+3.39%	228B
NOVARTIS AG	+10.75%	214B
AMGEN INC.	+6.99%	165B

Other Pharmaceuticals

Medios AG

Equities

ILM1

DE000A1MMCC8

Pharmaceuticals

NVR: Medios AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

EPS Revisions